Xue Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xue Shen has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Hao Wu
Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, and School of Life Science and Technology, University of Electronic Science and Technology of China
4 shared publicationsChongxiu Shi
Engineering Research Center for Pharmaceuticals and Equipments of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu, 610106, PR China
3 shared publicationsHongping Yang
Engineering Research Center for Pharmaceuticals and Equipments of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu, 610106, PR China
3 shared publications- Qihang Ding
Department of Chemistry Korea University Seoul South Korea
3 shared publications Wenhao Li
Engineering Research Center for Pharmaceuticals and Equipments of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu, 610106, PR China
3 shared publicationsYungchang Chen
Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, and School of Life Science and Technology, University of Electronic Science and Technology of China
3 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (41)
Mechanotherapy enhances nanodrug uptake by overcoming the actin cytoskeleton damping effect
Efficient nanodrug therapy in solid tumors is limited not only by extracellular barriers but also by the mechanical state of the plasma membrane (PM). Although mechanotherapy remodels the extracellular matrix (ECM) and improves tissue-level delivery, its effect on transmembrane transport remains unclear. Here, we show that matrix stiffness is transmitted to the PM through the actomyosin cytoskeleton and thereby regulates nanoparticle (NP) uptake. Within a hepatocellular carcinoma-relevant stiffness range, matrix stiffening promoted excessive F-actin polymerization and stress-fiber formation, producing a mechanically damped PM–actin interface that resisted membrane deformation and suppressed NP uptake. Pharmacological and genetic perturbations indicated that this mechanical barrier was reversible. In vivo, β-aminopropionitrile-mediated tumor softening loosened ECM architecture, increased NP penetration, and promoted cellular uptake by reducing F-actin-associated mechanical resistance. Intratumoral spatial analyses and paired bilateral tumor experiments further supported local regulation of NP uptake by the actomyosin state under matched matrix conditions. Combined tumor softening and donafenib-loaded PLGA NPs reduced endpoint tumor weight by 87.8% relative to free donafenib but increased pulmonary metastasis, revealing a potential efficacy-safety trade-off. These findings identify a multiscale mechanical mechanism linking tumor-matrix mechanics to nanomedicine delivery and the PM–actin interface as a potential therapeutic target.
- 8 October 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (41)
Open AccessMechanotherapy enhances nanodrug uptake by overcoming the actin cytoskeleton damping effect
Efficient nanodrug therapy in solid tumors is limited not only by extracellular barriers but also by the mechanical state of the plasma membrane (PM). Although mechanotherapy remodels the extracellular matrix (ECM) and improves tissue-level delivery, its effect on transmembrane transport remains unclear. Here, we show that matrix stiffness is transmitted to the PM through the actomyosin cytoskeleton and thereby regulates nanoparticle (NP) uptake. Within a hepatocellular carcinoma-relevant stiffness range, matrix stiffening promoted excessive F-actin polymerization and stress-fiber formation, producing a mechanically damped PM–actin interface that resisted membrane deformation and suppressed NP uptake. Pharmacological and genetic perturbations indicated that this mechanical barrier was reversible. In vivo, β-aminopropionitrile-mediated tumor softening loosened ECM architecture, increased NP penetration, and promoted cellular uptake by reducing F-actin-associated mechanical resistance. Intratumoral spatial analyses and paired bilateral tumor experiments further supported local regulation of NP uptake by the actomyosin state under matched matrix conditions. Combined tumor softening and donafenib-loaded PLGA NPs reduced endpoint tumor weight by 87.8% relative to free donafenib but increased pulmonary metastasis, revealing a potential efficacy-safety trade-off. These findings identify a multiscale mechanical mechanism linking tumor-matrix mechanics to nanomedicine delivery and the PM–actin interface as a potential therapeutic target.
- Open Access
- 1 March 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 57, 182-230
Selenium-derived bioactive enablers for advanced therapies: From molecular redox modulation to broad-spectrum disease applications
Selenium nanoparticles (SeNPs)-derived bioactives have garnered considerable attention in recent years due to their unique bioactivity, favorable biocompatibility, and versatile engineering potential in the field of disease therapy. This review systematically summarizes the primary strategies for SeNPs synthesis, encompassing chemical, biological, and physical approaches, and provides an in-depth discussion on their cytotoxic mechanisms mediated through oxidative stress modulation, caspase signaling activation, mitochondrial dysfunction, and adenosine triphosphate (ATP) depletion. Notably, we highlight the multidimensional protective functions of SeNPs in scavenging reactive oxygen species, modulating inflammatory cytokines, and reshaping the immune microenvironment, elucidating their pivotal roles in antioxidation, anti-inflammation, and immune regulation. Furthermore, the review outlines the cutting-edge advances of SeNPs-derived bioactives in cancer treatment, antibacterial applications, inflammatory diseases treatment, radiation protection, reversing acute kidney injury (AKI), and antiviral applications, positioning SeNPs as next-generation therapeutic platforms. This review establishes a translational roadmap for selenium-enabled therapeutics, bridging molecular redox modulation to multimodal disease interventions, with forward-looking insights into their evolution as targeted bioactives.
- 1 March 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 57, 182-230
Open AccessSelenium-derived bioactive enablers for advanced therapies: From molecular redox modulation to broad-spectrum disease applications
Selenium nanoparticles (SeNPs)-derived bioactives have garnered considerable attention in recent years due to their unique bioactivity, favorable biocompatibility, and versatile engineering potential in the field of disease therapy. This review systematically summarizes the primary strategies for SeNPs synthesis, encompassing chemical, biological, and physical approaches, and provides an in-depth discussion on their cytotoxic mechanisms mediated through oxidative stress modulation, caspase signaling activation, mitochondrial dysfunction, and adenosine triphosphate (ATP) depletion. Notably, we highlight the multidimensional protective functions of SeNPs in scavenging reactive oxygen species, modulating inflammatory cytokines, and reshaping the immune microenvironment, elucidating their pivotal roles in antioxidation, anti-inflammation, and immune regulation. Furthermore, the review outlines the cutting-edge advances of SeNPs-derived bioactives in cancer treatment, antibacterial applications, inflammatory diseases treatment, radiation protection, reversing acute kidney injury (AKI), and antiviral applications, positioning SeNPs as next-generation therapeutic platforms. This review establishes a translational roadmap for selenium-enabled therapeutics, bridging molecular redox modulation to multimodal disease interventions, with forward-looking insights into their evolution as targeted bioactives.
- Open Access
- 9 October 2025
- Published by Elsevier in Materials Today Bio
- Vol. 35, 102384
Microenvironment-responsive size-adaptive nanoparticles: hyaluronidase/acid/NIR light activation for deep-penetration trimodal therapy
- 9 October 2025
- Published by Elsevier in Materials Today Bio
- Vol. 35, 102384
Open AccessMicroenvironment-responsive size-adaptive nanoparticles: hyaluronidase/acid/NIR light activation for deep-penetration trimodal therapy
- Open Access
- 15 September 2025
- Published by Wiley in Advanced Materials
- Vol. 38 (1) , e13609
Tailoring Advanced Metal‐Based Nanomedicines for Adaptable Nanodynamic Disease Therapies and Theranostics
Advanced metal‐based nanomaterials (MBNs) represent a dynamic frontier in nanomedicine, offering a versatile platform for next‐generation diagnostics and therapeutics. Their tunable structures and catalytic, optical, and magnetic properties enable diverse nanodynamic therapies (NDTs), including photodynamic, chemodynamic, sonodynamic, thermodynamic, piezoelectric, radiodynamic, and magnetodynamic modalities. In addition to the well‐established tumor ablation, MBNs also feature potent antimicrobial and antiviral activity, functioning via reactive oxygen species generation, immune modulation, and biofilm disruption. Recent developments in metal–organic frameworks, metal–phenolic networks, and 2D metal nanosheets have expanded the toolkit for precision drug delivery, imaging‐guided therapy, and bioresponsive release strategies. This comprehensive review highlights the structural design principles, therapeutic mechanisms, and versatile biomedical applications of emerging MBN platforms, emphasizing synergistic treatment strategies and their role in overcoming hypoxia, multidrug resistance, and immunosuppression. Despite their promise, clinical translation remains hindered by unresolved issues in long‐term biosafety, biodegradation, and scalable manufacturing. Future efforts are expected to focus on tailoring intelligent nanostructures with optimized pharmacokinetics, integrating multimodal imaging with real‐time therapeutic feedback, and ensuring regulatory compliance. Continued innovation at the interface of materials science, biology, and medicine will be essential for transforming MBN‐based systems into clinically viable tools for oncology, infectious disease control, and personalized medicine.
- 15 September 2025
- Published by Wiley in Advanced Materials
- Vol. 38 (1) , e13609
Open AccessTailoring Advanced Metal‐Based Nanomedicines for Adaptable Nanodynamic Disease Therapies and Theranostics
Advanced metal‐based nanomaterials (MBNs) represent a dynamic frontier in nanomedicine, offering a versatile platform for next‐generation diagnostics and therapeutics. Their tunable structures and catalytic, optical, and magnetic properties enable diverse nanodynamic therapies (NDTs), including photodynamic, chemodynamic, sonodynamic, thermodynamic, piezoelectric, radiodynamic, and magnetodynamic modalities. In addition to the well‐established tumor ablation, MBNs also feature potent antimicrobial and antiviral activity, functioning via reactive oxygen species generation, immune modulation, and biofilm disruption. Recent developments in metal–organic frameworks, metal–phenolic networks, and 2D metal nanosheets have expanded the toolkit for precision drug delivery, imaging‐guided therapy, and bioresponsive release strategies. This comprehensive review highlights the structural design principles, therapeutic mechanisms, and versatile biomedical applications of emerging MBN platforms, emphasizing synergistic treatment strategies and their role in overcoming hypoxia, multidrug resistance, and immunosuppression. Despite their promise, clinical translation remains hindered by unresolved issues in long‐term biosafety, biodegradation, and scalable manufacturing. Future efforts are expected to focus on tailoring intelligent nanostructures with optimized pharmacokinetics, integrating multimodal imaging with real‐time therapeutic feedback, and ensuring regulatory compliance. Continued innovation at the interface of materials science, biology, and medicine will be essential for transforming MBN‐based systems into clinically viable tools for oncology, infectious disease control, and personalized medicine.
- 2 September 2025
- Published by Springer Nature in Science China Chemistry
- Vol. 68 (11) , 5451-5482
Poly(lactic-co-glycolic acid) nanomedicine for inflammatory bowel disease: targeted delivery and integrated diagnostics toward precision treatment
- 2 September 2025
- Published by Springer Nature in Science China Chemistry
- Vol. 68 (11) , 5451-5482
Poly(lactic-co-glycolic acid) nanomedicine for inflammatory bowel disease: targeted delivery and integrated diagnostics toward precision treatment